Development of Camera Based Gait Quality Measure for Persons With Multiple Sclerosis

Recruiting Observational Study
Multiple Sclerosis Multiple Sclerosis, Secondary Progressive Multiple Sclerosis Relapse Multiple Sclerosis, Relapsing-Remitting
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 75
Sex
Any
Study type
Observational
Participants needed
40 (estimated)
Sponsor
Shirley Ryan AbilityLab · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The purpose of this study is to develop a measurement of walking quality, called Gait Deviation Index (GDI) for people with Multiple Sclerosis (MS).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria: * Diagnosis of relapsing form of MS (including relapsing-remitting MS and secondary progressive MS) * Able to ambulate overground * Relapse free for at least 1 month * Age ≥18 and ≤ 75 years * Participants using dalfampridine will be eligible if taking the same daily dose for at…
Contacts

Weena Dee

312-328-7503

wdee@sralab.org

CONTACT

Alex Barry

312-238-1435

abarry@sralab.org

CONTACT